After being severely impacted by COVID-19, the THYmine 2 study needed additional funding for a clinical trials manager to secure its viability and ensure the study was running at the highest standard across all five of its sites.
At the time of making the application to GCF, the team led by Dr Nuala Helsby at the University of Auckland were some 70 patients short of the 200 needed to make the study viable. Thanks to the generosity of GCF supporters, the last 6 months have seen this potentially life-saving investigation reach 159 of the 200 patients needed by February 2022, going a long way to ensuring the viability of this vital study.
Dr Helsby said, “We are most grateful for this Gut Cancer Foundation funding which enables continued recruitment and study management. To date, one hundred and fifty-six people with gastrointestinal cancer, breast cancer or metastatic breast cancer in New Zealand have taken part in this study. We hope to recruit as close to the 200-participant target as possible in the time we have remaining”.
Read more about the THYmine2 study here.